These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1285 related articles for article (PubMed ID: 32108133)

  • 1. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyanidin-3-glucoside suppresses the progression of lung adenocarcinoma by downregulating TP53I3 and inhibiting PI3K/AKT/mTOR pathway.
    Chen X; Zhang W; Xu X
    World J Surg Oncol; 2021 Aug; 19(1):232. PubMed ID: 34362378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling.
    Liu Z; Hu Z; Cai X; Liu S
    Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TM6SF1 suppresses the progression of lung adenocarcinoma and M2 macrophage polarization by inactivating the PI3K/AKT/mtor pathway.
    Huang S; Zhao H; Lou X; Chen D; Shi C; Ren Z
    Biochem Biophys Res Commun; 2024 Jul; 718():149983. PubMed ID: 38718735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
    Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma.
    Wu Q; Wang YB; Che XW; Wang H; Wang W
    J Integr Med; 2023 May; 21(3):268-276. PubMed ID: 37069006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway.
    Li Y; Wang S; Jin K; Jin W; Si L; Zhang H; Tian H
    Thorac Cancer; 2023 Apr; 14(12):1077-1088. PubMed ID: 36919755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
    Zhu HE; Yin JY; Chen DX; He S; Chen H
    Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLITRK6 promotes the progression of lung adenocarcinoma by regulating PI3K/AKT/mTOR signaling and Warburg effect.
    Yu F; Zhao X; Li M; Meng M
    Apoptosis; 2023 Aug; 28(7-8):1216-1225. PubMed ID: 37219677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway.
    Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H
    Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-218 regulates the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting BMI-1.
    Xu L; Sun HB; Xu ZN; Han XL; Yin YY; Zheng Y; Zhao Y; Wang ZX
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7978-7988. PubMed ID: 31599423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA (let-7b-5p)-targeted DARS2 regulates lung adenocarcinoma growth by PI3K/AKT signaling pathway.
    Xu Y; Chen X
    Oncol Res; 2024; 32(3):517-528. PubMed ID: 38361754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR signaling pathway.
    Liu C; Wang Y; Dao Y; Wang S; Hou F; Yang Z; Liu P; Lv J; Lv L; Li G; Zhou Y; Deng Z
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(1):99-112. PubMed ID: 35130633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway.
    Gu X; Zhou L; Chen L; Pan H; Zhao R; Guang W; Wan G; Zhang P; Liu D; Deng LL; Zhao W; Lu C
    Biomed Res Int; 2021; 2021():6628682. PubMed ID: 33860045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition.
    Xuan YW; Liao M; Zhai WL; Peng LJ; Tang Y
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8411-8421. PubMed ID: 31646571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.
    Zhang H; Cao Y; Tang J; Wang R
    Biomed Res Int; 2022; 2022():9944847. PubMed ID: 35813221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K/AKT/mTOR pathway.
    Wang S; Liu B; Su Y; Wang N; Dong P; Xu X; Huang L; Li S; Gu J; Qiu Y; Deng J; Lin Z; Zhou Y
    Thorac Cancer; 2024 Mar; 15(8):630-641. PubMed ID: 38323374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
    Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K/AKT pathway in lung adenocarcinoma.
    Xue F; Jia Y; Zhao J
    Surg Oncol; 2020 Jun; 33():108-117. PubMed ID: 32561075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma.
    Ji Z; Pan X; Shang Y; Ni DT; Wu FL
    Tissue Cell; 2019 Dec; 61():44-50. PubMed ID: 31759406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.